Petracca, Maria
Saiote, Catarina
Bender, Heidi A.
Arias, Franchesca
Farrell, Colleen
Magioncalda, Paola
Martino, Matteo
Miller, Aaron
Northoff, Georg
Lublin, Fred
Inglese, Matilde
Article History
Received: 4 October 2016
Accepted: 15 March 2017
First Online: 21 April 2017
Competing interests
: Dr. Maria Petracca has nothing to disclose. Dr. Catarina Saiote has nothing to disclose. Dr. Bender has nothing to disclose. Ms. Arias has nothing to disclose. Ms. Colleen Farrell has nothing to disclose. Dr. Magioncalda has nothing to disclose. Dr. Martino has nothing to disclose. Dr. Aaron Miller has served as a consultant and/or participant in advisory board meetings for Genzyme/sanofi-aventis, Biogen Idec, Glaxo Smith Kline, EMD Serono (Merck Serono), Novartis, ONO, Acorda, Nuron Biotech, Teva, Questcor and Accordant Health Services. He has received research support from Acorda, Novartis, Genentech, Genzyme/sanofi-aventis, Biogen Idec, Roche, and Questcor. He has served as Editor of Continuum, a continuing medical education publication of the AAN and currently serves as Editor of Continuum Audio. He is a member of the editorial board of Multiple Sclerosis and Related Disorders. He occasionally performs expert reviews of medical records or serves as an expert witness in medical malpractice cases. Dr. Northoff has nothing to disclose. Dr. Fred Lublin Sources of Funding for Research: Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; NIH; NMSS; Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis; Teva Neuroscience; Actelion; Sanofi-Aventis; Acorda; Questcor; Roche, Genentech; Celgene; Johnson & Johnson; Revalesio; Coronado Bioscience, Genzyme, MedImmune; Bristol-Myers Squibb, Xenoport, Receptos; Forward Pharma; Co-Chief Editor: Multiple Sclerosis and Related Diseases; Stock Ownership: Cognition Pharmaceuticals, Inc. Dr. Matilde Inglese has received research grants from NIH, NMSS, Novartis Pharmaceuticals Corp., Teva Neuroscience. None of the competing financial interests have influenced the presented work in any stage from conception to analysis and publication.